Eli Lilly & Co. is buying three clinical-stage vaccine developers for as much as $3.8 billion, leveraging its obesity-fueled ...

Via the deals, Lilly is buying biotechs with lead programmes in preventing shingles, bacteria, and Epstein-Barr Virus.

The deals give Lilly vaccines targeting shingles, bacterial pathogens, and Epstein-Barr virus as it expands beyond weight ...

The drugmaker said it would spend up to $4 billion to acquire small companies exploring vaccines for shingles, Epstein-Barr ...

Eli Lilly has agreed to acquire three privately-held developers of vaccines for infectious diseases for a combined up-to-$3.83 billion cash, in deals intended to expand the acquisitive pharma giant’s ...

By Sriparna Roy May 26 (Reuters) - Eli Lilly said on Tuesday it will buy three vaccine developers in deals worth up to $3.8 billion in combined value, signaling its push into infectious disease ...

On May 26, Reuters reported that Eli Lilly and Company (NYSE:LLY) plans to acquire three vaccine developers in deals worth up ...

Eli Lilly and Company is pivoting significantly toward infectious disease prevention by executing agreements to buy three ...

Eli Lilly (LLY) stock is in focus as the company agrees to buy three vaccine developers in deals worth up to $4B in total. Read more here.

LimmaTech's lead program targets S. aureus, a major cause of surgical-site infections Vaccine Company acquisition includes experimental vaccine for Epstein-Barr virus Curevo is developing shingles ...